Professor

Star Mountain Capital Adds Former Dallas Fed CEO, Goldman Sachs Vice Chairman, Robert Kaplan, as Senior Advisor

Retrieved on: 
Tuesday, February 13, 2024
Asset Management, Professional Services, Finance, Federal Reserve Bank, Advisory board, Senior, Baker Institute, Draper Richards Kaplan Foundation, Professor, Project, Friends, Star, Ford Foundation, Advisory Council, State Street Corporation, Senior advisor, Trustee, Harvard University endowment, Interim, Starr Mountain, Investment banking, Goldman Sachs, Harvard Medical School, Project ALS, Harvard Business School, Book, Management

Star Mountain Capital , LLC (“Star Mountain”), a rapidly growing specialized private credit and secondaries investment firm targeting systematic alpha and low market correlated returns for its global institutional and high-net-worth investors is pleased to announce that Robert Kaplan has joined as Senior Advisor.

Key Points: 
  • Star Mountain Capital , LLC (“Star Mountain”), a rapidly growing specialized private credit and secondaries investment firm targeting systematic alpha and low market correlated returns for its global institutional and high-net-worth investors is pleased to announce that Robert Kaplan has joined as Senior Advisor.
  • View the full release here: https://www.businesswire.com/news/home/20240213968210/en/
    Robert S. Kaplan, Star Mountain Capital Senior Advisor (Photo: Business Wire)
    Robert Kaplan has over 40 years of investment management, business management, monetary policy, investment banking, and leadership experience.
  • His previous positions include CEO and President of the Federal Reserve Bank of Dallas, Vice Chairman of Investment Banking and Investment Management Divisions of Goldman Sachs, and Professor and Senior Associate Dean of Harvard Business School.
  • “We are honored to have Rob join Star Mountain as an aligned Senior Advisor bringing extensive investment, strategic leadership, business management and governance experience,” said Brett Hickey , Star Mountain Capital Founder & CEO.

Open Institute of Technology (OPIT) Expands Curricula and Enrollment to the United States

Retrieved on: 
Tuesday, February 13, 2024
Institution, Fortune 500, Research, Computer science, ECA, World Education Services, Bachelor's degree, Catalog, WES, University, EQF, Accreditation, Acceleration, Master's degree, World Economic Forum, Professor, Environment, Student, Management

That so-called mismatch, accelerated by the advent of AI, is generated by too much theory and too little practical approach.

Key Points: 
  • That so-called mismatch, accelerated by the advent of AI, is generated by too much theory and too little practical approach.
  • OPIT’s student-centric approach is complemented by a robust support system, including dedicated tutors available 7/7, class coordinators, and career services.
  • Professors from around the world bring real-world experience as technology leaders from Fortune 500 companies and esteemed academia alike.
  • OPIT currently offers the following Bachelor's and Master's degrees, with plans to expand beginning in September 2024.

New Study Redefines Reconstructive Surgery

Retrieved on: 
Tuesday, February 13, 2024
Hospital, University Medical Center, Professor, Manuscript, Risk, AG, Disease, Health, Patient, Dentistry

BILLERBECK, Germany, Feb. 13, 2024 /PRNewswire/ -- In a study led by Prof. Dragu, Professor and Head of the Plastic Surgery Department at the University Medical Center in Dresden, Germany, the effectiveness of MatriDerm®, a dermal template manufactured by MedSkin Solutions Dr Suwelack, AG, has been demonstrated. The new publication, which marks a significant advancement in reconstructive surgery, highlights MatriDerm®'s role in reducing operating room (OR) time, avoiding flap surgery in up to 80% of cases, and eliminating donor site morbidities associated with traditional flap procedures.

Key Points: 
  • The new publication, which marks a significant advancement in reconstructive surgery, highlights MatriDerm®'s role in reducing operating room (OR) time, avoiding flap surgery in up to 80% of cases, and eliminating donor site morbidities associated with traditional flap procedures.
  • This study is truly significant in not only impacting clinical practice but also underlines the economic benefits of MatriDerm®."
  • MatriDerm®'s ability to avoid complex flap surgery in most cases of this published specific morbid patient group represents a major shift in current treatment paradigms.
  • This offers the patients a less invasive but comparable and successful reconstructive result."

New Study Redefines Reconstructive Surgery

Retrieved on: 
Tuesday, February 13, 2024
Hospital, University Medical Center, Professor, Manuscript, Risk, AG, Disease, Health, Patient, Dentistry

BILLERBECK, Germany, Feb. 13, 2024 /PRNewswire/ -- In a study led by Prof. Dragu, Professor and Head of the Plastic Surgery Department at the University Medical Center in Dresden, Germany, the effectiveness of MatriDerm®, a dermal template manufactured by MedSkin Solutions Dr Suwelack, AG, has been demonstrated. The new publication, which marks a significant advancement in reconstructive surgery, highlights MatriDerm®'s role in reducing operating room (OR) time, avoiding flap surgery in up to 80% of cases, and eliminating donor site morbidities associated with traditional flap procedures.

Key Points: 
  • The new publication, which marks a significant advancement in reconstructive surgery, highlights MatriDerm®'s role in reducing operating room (OR) time, avoiding flap surgery in up to 80% of cases, and eliminating donor site morbidities associated with traditional flap procedures.
  • This study is truly significant in not only impacting clinical practice but also underlines the economic benefits of MatriDerm®."
  • MatriDerm®'s ability to avoid complex flap surgery in most cases of this published specific morbid patient group represents a major shift in current treatment paradigms.
  • This offers the patients a less invasive but comparable and successful reconstructive result."

Enigma Biomedical - USA Announces Appointment of Hartmuth Kolb, PhD as Chief Scientific Officer

Retrieved on: 
Tuesday, February 13, 2024
Research, General Health, Radiology, Pharmaceutical, Biometrics, Medical Devices, Health Technology, Science, Biotechnology, Neurology, Other Science, Health, Organic chemistry, FNIH, Neuroscience, Doctor of Philosophy, Nobel Prize in Chemistry, NIH, Professor, SVP, Johnson & Johnson, Hartmuth C. Kolb, Neurodegenerative disease, Imperial College London, Biomedicine, Biomarker, Siemens Healthineers, Enigma, EB, Scripps Research, CNS, Associate, Disease, CSO, Diagnosis, PET, Click chemistry, Central nervous system disease, Nobel Prize, Management

Enigma Biomedical USA (EB) today announced the appointment of Hartmuth Kolb, PhD as Chief Science Officer (CSO).

Key Points: 
  • Enigma Biomedical USA (EB) today announced the appointment of Hartmuth Kolb, PhD as Chief Science Officer (CSO).
  • Dr. Kolb’s passion for innovation and scientific rigor has driven his extensive career and broad recognition.
  • He will join Enigma at the beginning of March, 2024.
  • In his 10 year tenure at Johnson & Johnson Innovative Medicine, he served as the Vice President, Neuroscience Biomarkers and Global Head of Imaging.

TJC Listed in HEC Paris-Dow Jones Large Buyout Performance 2023 Rankings

Retrieved on: 
Thursday, February 8, 2024
Finance, Professional Services, Other Professional Services, Asset Management, Fintech, HEC Paris, HEC, Private equity, TJC, Professor

TJC LP (“TJC” or “the Firm”), a middle-market private equity firm investing primarily in North America, is pleased to announce that the Firm has been ranked #11 on the HEC Paris-Dow Jones 2023 Global Ranking: Top 20 Private Equity Firms in Large Buyout Performance.

Key Points: 
  • TJC LP (“TJC” or “the Firm”), a middle-market private equity firm investing primarily in North America, is pleased to announce that the Firm has been ranked #11 on the HEC Paris-Dow Jones 2023 Global Ranking: Top 20 Private Equity Firms in Large Buyout Performance.
  • “We are proud to be recognized by HEC Paris and Dow Jones as one of the best performing large buyout firms,” said Rich Caputo, Chairman and Chief Executive Partner of TJC.
  • The HEC-Dow Jones Ranking draws on private equity fund performance data reported directly to HEC-Dow Jones.
  • TJC provided information to HEC-Dow Jones upon request to inform the HEC-Dow Jones Ranking.

Cosmo Prof Leads Textured Hair Education Through Fourth Annual World of Texture Virtual Event

Retrieved on: 
Wednesday, February 7, 2024
Life, Schwarzkopf, Continuing education, Wella, Olaplex, DevaCurl, Doux, Education, CE, Student, Professor, Fashion design

DENTON, Texas, Feb. 7, 2024 /PRNewswire/ -- The demand for well-rounded beauty professionals continues to grow, with clients seeking local experts proficient in a diverse range of hair types. With over 65% of the population having textured hair and current cosmetology school courses dedicating only a small portion to textured hair education, stylists are eager to learn the essential skills needed to serve their communities best. As the need for further access to textured hair education heightens, Cosmo Prof aims to help stylists take the initiative to continue their education and service every client with top knowledge from leaders across the industry.

Key Points: 
  • Cosmo Prof continues to provide high-quality educational resources through its virtual platform, inviting stylists to the World of Texture event to enhance their understanding of texture and curl patterns within the beauty industry.
  • As the need for further access to textured hair education heightens, Cosmo Prof aims to help stylists take the initiative to continue their education and service every client with top knowledge from leaders across the industry.
  • Bringing back World of Texture for its fourth year on February 26th, 2024 - Cosmo Prof's virtual event aims to serve as a hub for students, professionals and educators to come together and deepen their understanding of texture and curl patterns within the beauty industry.
  • Through February 25th, beauty professionals can find more information and sign up for the World of Texture event at https://www.cosmoprofbeauty.com/world-of-texture .

Children's Health and UT Southwestern Announce Plans for Transformative New Pediatric Campus in Dallas' Southwestern Medical District

Retrieved on: 
Wednesday, February 7, 2024
Partnership, OMICS Publishing Group, UTSW, Nursing, Population growth, Science, Research, Remake, Children's Medical Center Dallas, Teaching hospital, Rodale, Inc., Medical Center, Environment, Patient, Child, Investment, Health, Mockingbird Lane, News, Training, Bed, Redbird, Professor, Organization, Hospital

DALLAS, Feb. 7, 2024 /PRNewswire/ -- Children's HealthSM and UT Southwestern Medical Center unveiled plans for a new $5 billion pediatric health campus in Dallas' Southwestern Medical District today. Spanning more than 33 acres, the new pediatric campus offers a patient-centric design that can meet the rapidly increasing need for more pediatric services from the most common to the most complex. It will serve as a joint hub for innovation, academic research and training, and the development of life-saving technologies to provide exemplary care for the youngest members of our community.

Key Points: 
  • New Multi-tower Hospital to Replace Children's Medical Center Dallas to Meet Surging Demand for Pediatric Care, Research and Training
    DALLAS, Feb. 7, 2024 /PRNewswire/ -- Children's HealthSM and UT Southwestern Medical Center unveiled plans for a new $5 billion pediatric health campus in Dallas' Southwestern Medical District today.
  • Life-changing treatments, pioneering research, and training the next generation of pediatric providers are the hallmarks of the Children's Health and UT Southwestern legacy.
  • The new pediatric campus adds to the ongoing investments Children's Health continues to make to meet the region's growing pediatric medical and surgical needs.
  • In 2025, Children's Health will occupy the second floor of the 150,000-square-foot UT Southwestern Medical Center at RedBird, part of the Reimagine RedBird development.

Orexo's OX640 development results to be presented at the 2024 AAAAI Annual Meeting in Washington, DC

Retrieved on: 
Tuesday, February 6, 2024
AAAAI, Research, Division, Patient, Queen, American Academy, SVP, Allergic rhinitis, Bioavailability, University, Adrenaline, Treatment, Annual general meeting, Professor, Pharmaceutical industry

), (STO:ORX) (OTCQX:ORXOY), today announces the presentation of its nasal epinephrine powder product OX640 at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.

Key Points: 
  • ), (STO:ORX) (OTCQX:ORXOY), today announces the presentation of its nasal epinephrine powder product OX640 at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.
  • The AAAAI annual meeting is taking place in Washington, DC, February 23-26, 2024.
  • OX640 is Orexo's nasal epinephrine powder product for the acute treatment of severe allergic reactions, including anaphylaxis.
  • Robert Rönn, SVP and Head of R&D, said: "We are honoured that the AAAAI program committee selected our OX640 abstract to be presented at this high-profile late breaking oral abstract session.

Orexo's OX640 development results to be presented at the 2024 AAAAI Annual Meeting in Washington, DC

Retrieved on: 
Tuesday, February 6, 2024
AAAAI, Research, Division, Patient, Queen, American Academy, SVP, Allergic rhinitis, Bioavailability, University, Adrenaline, Treatment, Annual general meeting, Professor, Pharmaceutical industry

), (STO:ORX) (OTCQX:ORXOY), today announces the presentation of its nasal epinephrine powder product OX640 at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.

Key Points: 
  • ), (STO:ORX) (OTCQX:ORXOY), today announces the presentation of its nasal epinephrine powder product OX640 at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.
  • The AAAAI annual meeting is taking place in Washington, DC, February 23-26, 2024.
  • OX640 is Orexo's nasal epinephrine powder product for the acute treatment of severe allergic reactions, including anaphylaxis.
  • Robert Rönn, SVP and Head of R&D, said: "We are honoured that the AAAAI program committee selected our OX640 abstract to be presented at this high-profile late breaking oral abstract session.